Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a ...

The biotech could play a significant role in a national effort to combat cancer.

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine ...

Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run ...

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...

In the recent earnings report, Moderna reiterated its forecast for as much as 10% revenue growth in the current year thanks ...

Moderna ( MRNA) rose roughly 5% and Eli Lilly ( LLY) added nearly 3% to rank among the day’s best-performing stocks in the ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results evaluating its personalized cancer vaccine, intismeran ...

Moderna ( (MRNA)) has issued an update. On September 30, 2026, Moderna announced it is adding a Chief Operating Officer role as it expands into oncology and scales its infectious disease franchise, ...

Moderna Inc. stocks have been trading up by 14.2 percent after promising late-stage mRNA vaccine trial results boosted ...